Image-based assessment of extracellular mucin-to-tumor area predicts consensus molecular subtypes (CMS) in colorectal cancer.
Journal
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
30
06
2021
accepted:
05
08
2021
revised:
05
08
2021
pubmed:
4
9
2021
medline:
5
4
2022
entrez:
3
9
2021
Statut:
ppublish
Résumé
The backbone of all colorectal cancer classifications including the consensus molecular subtypes (CMS) highlights microsatellite instability (MSI) as a key molecular pathway. Although mucinous histology (generally defined as >50% extracellular mucin-to-tumor area) is a "typical" feature of MSI, it is not limited to this subgroup. Here, we investigate the association of CMS classification and mucin-to-tumor area quantified using a deep learning algorithm, and the expression of specific mucins in predicting CMS groups and clinical outcome. A weakly supervised segmentation method was developed to quantify extracellular mucin-to-tumor area in H&E images. Performance was compared to two pathologists' scores, then applied to two cohorts: (1) TCGA (n = 871 slides/412 patients) used for mucin-CMS group correlation and (2) Bern (n = 775 slides/517 patients) for histopathological correlations and next-generation Tissue Microarray construction. TCGA and CPTAC (n = 85 patients) were used to further validate mucin detection and CMS classification by gene and protein expression analysis for MUC2, MUC4, MUC5AC and MUC5B. An excellent inter-observer agreement between pathologists' scores and the algorithm was obtained (ICC = 0.92). In TCGA, mucinous tumors were predominantly CMS1 (25.7%), CMS3 (24.6%) and CMS4 (16.2%). Average mucin in CMS2 was 1.8%, indicating negligible amounts. RNA and protein expression of MUC2, MUC4, MUC5AC and MUC5B were low-to-absent in CMS2. MUC5AC protein expression correlated with aggressive tumor features (e.g., distant metastases (p = 0.0334), BRAF mutation (p < 0.0001), mismatch repair-deficiency (p < 0.0001), and unfavorable 5-year overall survival (44% versus 65% for positive/negative staining). MUC2 expression showed the opposite trend, correlating with less lymphatic (p = 0.0096) and venous vessel invasion (p = 0.0023), no impact on survival.The absence of mucin-expressing tumors in CMS2 provides an important phenotype-genotype correlation. Together with MSI, mucinous histology may help predict CMS classification using only histopathology and should be considered in future image classifiers of molecular subtypes.
Identifiants
pubmed: 34475526
doi: 10.1038/s41379-021-00894-8
pii: S0893-3952(22)00335-0
pmc: PMC8786661
doi:
Substances chimiques
Biomarkers, Tumor
0
Mucin-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
240-248Informations de copyright
© 2021. The Author(s).
Références
Gaiani, F., Marchesi, F., Negri, F., Greco, L., Malesci, A. & de’Angelis, G. L. et al. Heterogeneity of colorectal cancer progression: molecular gas and brakes. Int J Mol Sci. https://doi.org/10.3390/ijms22105246 (2021).
Pecci, F., Cantini, L., Bittoni, A., Lenci, E., Lupi, A. & Crocetti, S. et al. Beyond microsatellite instability: evolving strategies integrating immunotherapy for microsatellite stable colorectal cancer. Curr Treat Options Oncol. https://doi.org/10.1007/s11864-021-00870-z (2021).
Toh, J. W. T., Phan, K., Reza, F., Chapuis, P. & Spring, K. J. Rate of dissemination and prognosis in early and advanced stage colorectal cancer based on microsatellite instability status: Systematic review and meta-analysis. Int. J. Colorectal. Dis. 36, 1573–96 (2021).
doi: 10.1007/s00384-021-03874-1
Trullas, A., Delgado, J., Genazzani, A., Mueller-Berghaus, J., Migali, C. & Müller-Egert, S. et al. The ema assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer. ESMO Open https://doi.org/10.1016/j.esmoop.2021.100145 (2021).
Argilés, G., Tabernero, J., Labianca, R., Hochhauser, D., Salazar, R. & Iveson, T. et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31, 1291–305 (2020).
doi: 10.1016/j.annonc.2020.06.022
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A. & Soneson, C. et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350–6 (2015).
doi: 10.1038/nm.3967
Ten Hoorn, S., de Back, T. R., Sommeijer, D. W. & Vermeulen, L. Clinical value of consensus molecular subtypes in colorectal cancer: a systematic review and meta-analysis. J. Natl Cancer Inst. https://doi.org/10.1093/jnci/djab106 (2021).
Jenkins, M. A., Hayashi, S., O’Shea, A. M., Burgart, L. J., Smyrk, T. C. & Shimizu, D. et al. Pathology features in bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology 133, 48–56 (2007).
doi: 10.1053/j.gastro.2007.04.044
Reynolds, I. S., Furney, S. J., Kay, E. W., McNamara, D. A., Prehn, J. H. M. & Burke, J. P. Meta-analysis of the molecular associations of mucinous colorectal cancer. Br J. Surg. 106, 682–91 (2019).
doi: 10.1002/bjs.11142
Lugli, A., Kirsch, R., Ajioka, Y., Bosman, F., Cathomas, G. & Dawson, H. et al. Recommendations for reporting tumor budding in colorectal cancer based on the international tumor budding consensus conference (itbcc) 2016. Mod. Pathol. 30, 1299–311 (2017).
doi: 10.1038/modpathol.2017.46
Schafroth, C., Galván, J. A., Centeno, I., Koelzer, V. H., Dawson, H. E. & Sokol, L. et al. Ve1 immunohistochemistry predicts braf v600e mutation status and clinical outcome in colorectal cancer. Oncotarget 6, 41453–63 (2015).
doi: 10.18632/oncotarget.6162
Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–7 (2012).
doi: 10.1038/nature11252
Huang, M. N., McPherson, J. R., Cutcutache, I., Teh, B. T., Tan, P. & Rozen, S. G. Msiseq: Software for assessing microsatellite instability from catalogs of somatic mutations. Sci. Rep. https://doi.org/10.1038/srep13321 (2015).
Li, L., Feng, Q. & Wang, X. Premsim: an r package for predicting microsatellite instability from the expression profiling of a gene panel in cancer. Comput. Struct. Biotechnol. J. 18, 668–75 (2020).
doi: 10.1016/j.csbj.2020.03.007
Vasaikar, S., Huang, C., Wang, X., Petyuk, V. A., Savage, S. R. & Wen, B. et al. Proteogenomic analysis of human colon cancer reveals new therapeutic opportunities. Cell 177, 1035–49 (2019).
doi: 10.1016/j.cell.2019.03.030
Bankhead, P., Loughrey, M. B., Fernandez, J. A., Dombrowski, Y., McArt, D. G. & Dunne, P. D. et al. Qupath: Open-source software for digital pathology image analysis. Sci. Rep. https://doi.org/10.1038/s41598-017-17204-5 (2017).
Bychkov, D., Linder, N., Turkki, R., Nordling, S., Kovanen, P. E. & Verrill, C. et al. Deep learning based tissue analysis predicts outcome in colorectal cancer. Sci. Rep. https://doi.org/10.1038/s41598-018-21758-3 (2018).
Kather, J. N., Pearson, A. T., Halama, N., Jäger, D., Krause, J. & Loosen, S. H. et al. Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. Nat. Med. 25, 1054–6 (2019).
doi: 10.1038/s41591-019-0462-y
Nguyen, H. G., Blank, A., Dawson, H. E., Lugli, A. & Zlobec, I. Classification of colorectal tissue images from high throughput tissue microarrays by ensemble deep learning methods. Sci. Rep. https://doi.org/10.1038/s41598-021-81352-y (2021).
Simonyan, K. & Zisserman, A. Very deep convolutional networks for large-scale image recognition. ICLR https://arxiv.org/abs/1409.1556 (2015).
Sabour, S., Frosst, N. & Hinton, G. Dynamic routing between capsules. NeuIPS31, 3856–66 (2017)
Coebergh van den Braak, R. R. J., Ten Hoorn S., Sieuwerts A. M., Tuynman, J. B., Smid, M. & Wilting, S. M. et al. Interconnectivity between molecular subtypes and tumor stage in colorectal cancer. BMC Cancer https://doi.org/10.1186/s12885-020-07316-z (2020).
Rosty, C., Young, J. P., Walsh, M. D., Clendenning, M., Walters, R. J. & Pearson, S. et al. Colorectal carcinomas with kras mutation are associated with distinctive morphological and molecular features. Mod. Pathol. 26, 825–34 (2013).
doi: 10.1038/modpathol.2012.240
Jang, H. J., Lee, A., Kang, J., Song, I. H. & Lee, S. H. Prediction of clinically actionable genetic alterations from colorectal cancer histopathology images using deep learning. World J. Gastroenterol. 26, 6207–23 (2020).
doi: 10.3748/wjg.v26.i40.6207
Echle, A., Grabsch, H. I., Quirke, P., Van den Brandt, P. A., West, N. P. & Hutchins, G. G. A. et al. Clinical-grade detection of microsatellite instability in colorectal tumors by deep learning. Gastroenterology 159, 1406–16 (2020).
doi: 10.1053/j.gastro.2020.06.021
Noorbakhsh, J., Farahmand, S., Foroughi Pour, A., Namburi, S., Caruana, D. & Rimm, D., et al. Deep learning-based cross-classifications reveal conserved spatial behaviors within tumor histological images. Nat. Commun. https://doi.org/10.1038/s41467-020-20030-5 (2020).
Pothuraju, R., Rachagani, S., Krishn, S. R., Chaudhary, S., Krishna Nimmakayala, R. & Siddiqui, J. A. et al. Molecular implications of muc5ac-cd44 axis in colorectal cancer progression and chemoresistance. Mol. Cancer https://doi.org/10.1186/s12943-020-01156-y (2020).
Li, C., Zuo, D., Liu, T., Yin, L., Li, C. & Wang, L. Prognostic and clinicopathological significance of muc family members in colorectal cancer: a systematic review and meta-analysis. Gastroenterol. Res. Pract. https://doi.org/10.1155/2019/2391670 (2019).
Sirinukunwattana, K., Domingo, E., Richman, S. D., Redmond, K. L., Blake, A. & Verrill, C. et al. Image-based consensus molecular subtype (imcms) classification of colorectal cancer using deep learning. Gut 70, 544–54 (2021).
doi: 10.1136/gutjnl-2019-319866
Trinh, A., Lädrach, C., Dawson, H. E., Ten Hoorn, S., Kuppen, P. J. K. & Reimers, M. S. et al. Tumour budding is associated with the mesenchymal colon cancer subtype and ras/raf mutations: A study of 1320 colorectal cancers with consensus molecular subgroup (cms) data. Br. J. Cancer 119, 1244–51 (2018).
doi: 10.1038/s41416-018-0230-7